Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-06-25
DOI
10.2217/fon-2020-0299
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
- (2019) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
- (2019) Maeve A Lowery et al. Lancet Gastroenterology & Hepatology
- Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients
- (2019) Liang-Shuo Hu et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- 155OEfficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s
- (2018) B Tran et al. ANNALS OF ONCOLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
- (2016) Supriya K. Saha et al. ONCOLOGIST
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets
- (2015) Hwajeong Lee et al. JOURNAL OF CLINICAL PATHOLOGY
- Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma
- (2015) Gaya Spolverato et al. JAMA Surgery
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
- (2014) John Bridgewater et al. JOURNAL OF HEPATOLOGY
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
- (2011) Vito Guagnano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now